| Pan-cancer analysis of whole genomes Nature 578 (7793), 82-93, 2020 | 1703* | 2020 |
| The landscape of genomic alterations across childhood cancers SN Gröbner, BC Worst, J Weischenfeldt, I Buchhalter, K Kleinheinz, ... Nature 555 (7696), 321-327, 2018 | 1278 | 2018 |
| The whole-genome landscape of medulloblastoma subtypes PA Northcott, I Buchhalter, AS Morrissy, V Hovestadt, J Weischenfeldt, ... Nature 547 (7663), 311-317, 2017 | 957 | 2017 |
| Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial GW Robinson, VA Rudneva, I Buchhalter, CA Billups, SM Waszak, ... The Lancet Oncology 19 (6), 768-784, 2018 | 202 | 2018 |
| Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma V Maximov, Z Chen, Y Wei, MH Robinson, CJ Herting, NS Shanmugam, ... Nature communications 10 (1), 2410, 2019 | 87 | 2019 |
| Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma C Lee, VA Rudneva, S Erkek, M Zapatka, LQ Chau, ... Nature communications 10 (1), 332, 2019 | 69 | 2019 |
| Comprehensive molecular and clinicopathologic analysis of 200 pulmonary invasive mucinous adenocarcinomas identifies distinct characteristics of molecular subtypes JC Chang, M Offin, C Falcon, D Brown, BR Houck-Loomis, F Meng, ... Clinical Cancer Research 27 (14), 4066-4076, 2021 | 51 | 2021 |
| Phase II study of nonmetastatic desmoplastic medulloblastoma in children younger than 4 years of age: a report of the Children’s Oncology Group (ACNS1221) L Lafay-Cousin, E Bouffet, D Strother, V Rudneva, C Hawkins, C Eberhart, ... Journal of Clinical Oncology 38 (3), 223, 2020 | 46 | 2020 |
| Synergism of checkpoint inhibitors and peptide receptor radionuclide therapy in the treatment of pituitary carcinoma AL Lin, V Tabar, RJ Young, M Cohen, J Cuaron, TJ Yang, M Rosenblum, ... Journal of the Endocrine Society 5 (10), bvab133, 2021 | 27 | 2021 |
| Avelumab plus talazoparib in patients with BRCA1/2-or ATM-altered advanced solid tumors: results from JAVELIN BRCA/ATM, an open-label, multicenter, phase 2b, tumor-agnostic trial AM Schram, N Colombo, E Arrowsmith, V Narayan, K Yonemori, ... JAMA oncology 9 (1), 29-39, 2023 | 26 | 2023 |
| ICGC PedBrain-Seq Project; ICGC MMML-Seq Project SN Gröbner, BC Worst, J Weischenfeldt, I Buchhalter, K Kleinheinz, ... The landscape of genomic alterations across childhood cancers. Nature 555 …, 2018 | 26 | 2018 |
| Author Correction: Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing I Cortés-Ciriano, JJK Lee, R Xi, D Jain, YL Jung, L Yang, D Gordenin, ... Nature genetics 55 (6), 1076-1076, 2023 | 1 | 2023 |
| Author Correction: Pan-cancer analysis of whole genomes Nature 614 (7948), E39-E39, 2023 | 1 | 2023 |
| MBCL-08. Molecular characterization of nodular desmoplastic medulloblastomas in young children treated on ACNS1221. A report from the Children Oncology Group L Lafay-Cousin, G Robinson, V Rudneva, P Northcott, C Billups, ... Neuro-Oncology 20 (suppl_2), i118-i119, 2018 | 1 | 2018 |
| MBCL-21. EARLY CHILDHOOD MEDULLOBLASTOMA: SUBGROUP-SPECIFIC SURVIVAL IN PATIENTS TREATED WITH SYSTEMIC CHEMOTHERAPY AND INTRAVENTRICULAR MTX TO AVOID CRANIOSPINAL RADIOTHERAPY M Mynarek, M Kool, U Schueller, K von Hoff, T Sharma, V Rudneva, ... Neuro-Oncology 20 (suppl_2), i121-i121, 2018 | 1 | 2018 |
| MBRS-34. Molecular characterization of recurrent medulloblastoma reveals an unexpectedly high incidence of secondary malignancy R Kumar, M Deng, VA Rudneva, GW Robinson, G Dhall, LJ Klesse, ... Neuro-oncology 20 (suppl_2), i135-i135, 2018 | 1 | 2018 |
| Applicability of coexpression networks analysis to anticancer drug targets discovery AE Ivliev, VA Rudneva, MG Sergeeva M.G. Mol Biol 44 (2), 326–333, 2010 | 1 | 2010 |
| 115 Comprehensive spatial, transcriptomic, and genomic analysis of immunogenic biliary tract cancer W Park, F Keane, HS Ozkan, A Richards, V Rudneva, D Khalil, K Soares, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Improved survival among patients with malignant pleural mesotheliomas who develop immune-related adverse events on immunotherapy. M Offin, JV Egger, CG McCarthy, V Rudneva, J Beattie, MS Ginsberg, ... Journal of Clinical Oncology 39 (15_suppl), 8556-8556, 2021 | | 2021 |
| PATH-54. MULTI-DIMENSIONAL MOLECULAR CHARACTERIZATION OF PATIENT-MATCHED MEDULLOBLASTOMA AT DIAGNOSIS AND RELAPSE R Kumar, M Deng, K Smith, APY Liu, V Rudneva, G Dhall, L Kleese, ... Neuro-Oncology 21 (Supplement_6), vi155-vi155, 2019 | | 2019 |
